539680 — GANGA PHARMACEUTICALS Income Statement
0.000.00%
- IN₹73.89m
- IN₹84.21m
- IN₹28.28m
Annual income statement for GANGA PHARMACEUTICALS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 25.9 | 27.4 | 26.4 | 28.3 |
| Cost of Revenue | ||||
| Gross Profit | 13.5 | 14.9 | 14.2 | 15.2 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 26.4 | 27.3 | 28 | 28.4 |
| Operating Profit | -0.515 | 0.084 | -1.63 | -0.168 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 0.531 | 0.633 | 0.947 | 1.29 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 0.393 | 0.466 | 0.79 | 1.01 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 0.393 | 0.466 | 0.79 | 1.01 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 0.393 | 0.466 | 0.79 | 1.01 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.097 | 0.071 | 0.12 | 0.172 |